Hepatitis B: Updates from Precision BioSciences and Barinthus Biotherapeutics

Back to the "HIV and Co-Infections News" list

Precision BioSciences submits first Clinical Trial Applications to initiate Phase 1 trial for PBGENE-HBV for the treatment of chronic hepatitis B

Precision BioSciences, Inc. announced that the Company submitted Clinical Trial Applications to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company’s wholly owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.

********************

Barinthus Bio completes enrollment for Phase 2b HBV003 clinical trial in chronic hepatitis B

Barinthus Biotherapeutics plc announced the completion of enrollment for HBV003 – a Phase 2b clinical trial of VTP-300 in adults with chronic hepatitis B (CHB). The Phase 2b HBV003 trial has enrolled 121 participants and is designed to obtain critical dosing information for a potential functional cure regimen for CHB, with participants receiving VTP-300 and low-dose (LD) nivolumab.

********************

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.